Severe Asthma – Dupilumab (Dupixent®)
Dupilumab (Dupixent®) for the treatment of severe asthma in adults and adolescents 12 years and older is reimbursed on the High Tech Arrangement from 1st November 2023. A Managed Access Protocol (MAP) is in place for dupilumab for the treatment of severe asthma. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of dupilumab for the treatment of severe asthma under the High Tech Arrangement.
Applications for reimbursement approval for dupilumab for the treatment of severe asthma under the High Tech Arrangement will only be considered from consultant respiratory physicians registered with the Irish Medical Council, who specialise in severe asthma and are practicing within a severe asthma centre, and who have agreed to the terms of this MAP and been approved by the HSE. The approved consultant must submit an application for individual reimbursement approval for each patient.
The prescribing of dupilumab (Dupixent®) for approved patients for the treatment of severe asthma under the High Tech Arrangement will be confined to the approved consultants and their teams.
A copy of the HSE-Managed Access Protocol for dupilumab (Dupixent®) for the treatment of severe asthma can be found in the Related Files section below.
For further information, please contact email@example.com.